Rychak, Emily

Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 814

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs

Chamberlain, P. P., Lopez-Girona, A., Miller, K., Carmel, G., Pagarigan, B., Chie-Leon, B., Rychak, E., Corral, L. G., Ren, Y. J., Wang, M., et al. (2014) · Nature Structural & Molecular Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 531

CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells

Surka, C., Jin, L., Mbong, N., Lu, C.-C., Jang, I. S., Rychak, E., Mendy, D., Clayton, T., Tindall, E., Hsu, C., et al. (2021) · Blood

Protein Degradation and InhibitorsAcute Myeloid Leukemia Research

Cited by 229

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Hagner, P. R., Man, H.-W., Fontanillo, C., Wang, M., Couto, S., Breider, M., Bjorklund, C., Havens, C. G., Lu, G., Rychak, E., et al. (2015) · Blood

Protein Degradation and InhibitorsLymphoma Diagnosis and Treatment

Cited by 203

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

Gandhi, A. K., Mendy, D., Waldman, M., Chen, G., Rychak, E., Miller, K., Gaidarova, S., Ren, Y., Wang, M., Breider, M., et al. (2014) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 106

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Lopez-Girona, A., Havens, C. G., Lu, G., Rychak, E., Mendy, D., Gaffney, B., Surka, C., Lu, C.-C., Matyskiela, M., Khambatta, G., et al. (2019) · Blood

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 25